

**In the Specification:**

Please amend the specification as follows:

On Page 1, line 1, after the title, insert the following amended paragraph:

— **RELATED APPLICATIONS**

This a Continuation of U.S. Application Serial No. 09/579,403 filed May 25, 2000, which is a Continuation of U.S. Application Serial No. 09/336,402 filed June 18, 1999 which is This application is--a Continuation-in-part application of U.S. Serial No. 09/099.725 filed June 19, 1998. —

The paragraph beginning at Page 12, line 21 has been substituted with the following:

-- The rBPI(10-193)C132A expression vector, pING1742, was constructed as follows. The expression vector pING4155 was first constructed by ligating a *Bam*HI-*Bsa*I fragment containing the *neo* gene from pING3174 with a *Bsa*I-*Xho*I fragment containing the CMV promoter and rBPI<sub>21</sub> gene from pING4144 (including an optimized Kozak translation initiation site at residue -27 of the signal) and an *Xho*I-*Bam*HI fragment containing the mouse (kappa) light chain 3' untranslated region from pING4537 (pING3174, pING4144 and pING4537 are described in U.S. Patent No. 5,420,019, incorporated by reference). The resulting pING4155 vector contains the gene encoding rBPI<sub>21</sub> fused to the human IgG enhancer, the human CMV promoter, a 27 amino acid BPI leader sequence (amino acid residues -27 through -1 of SEQ ID NO: 2) and the mouse (kappa) light chain 3' untranslated region. It also contains the *neo* gene encoding neomycin phosphotransferase, for selection of transfectants resistant to the antibiotic Geneticin® (G418). --